BR112017019685A2 - composto, composição farmacêutica, uso de um composto ou um sal ou um solvato farmaceuticamente aceitável do mesmo, e, método para tratamento de uma doença ou condição - Google Patents
composto, composição farmacêutica, uso de um composto ou um sal ou um solvato farmaceuticamente aceitável do mesmo, e, método para tratamento de uma doença ou condiçãoInfo
- Publication number
- BR112017019685A2 BR112017019685A2 BR112017019685A BR112017019685A BR112017019685A2 BR 112017019685 A2 BR112017019685 A2 BR 112017019685A2 BR 112017019685 A BR112017019685 A BR 112017019685A BR 112017019685 A BR112017019685 A BR 112017019685A BR 112017019685 A2 BR112017019685 A2 BR 112017019685A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disease
- solvate
- treating
- condition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
a presente invenção é direcionada a compostos de pirimidina carboxamida da fórmula i, os quais são úteis como agentes terapêuticos para o tratamento de distúrbios do sistema nervoso central associados a fosfodiesterase 2 (pde2). a presente invenção também se refere ao uso de tais compostos para tratar distúrbios neurológicos e psiquiátricos, tais como esquizofrenia, psicose, doença de parkinson, demência por doença de parkinson (pdd) ou doença de huntington, e aquelas associadas a hipofunção estriada ou disfunção de gânglios basais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/074396 WO2016145614A1 (en) | 2015-03-17 | 2015-03-17 | Triazolyl pyrimidinone compounds as pde2 inhibitors |
PCT/US2016/021902 WO2016149058A1 (en) | 2015-03-17 | 2016-03-11 | Triazolyl pyrimidinone compounds as pde2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017019685A2 true BR112017019685A2 (pt) | 2018-05-15 |
Family
ID=56919578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017019685A BR112017019685A2 (pt) | 2015-03-17 | 2016-03-11 | composto, composição farmacêutica, uso de um composto ou um sal ou um solvato farmaceuticamente aceitável do mesmo, e, método para tratamento de uma doença ou condição |
Country Status (11)
Country | Link |
---|---|
US (1) | US10358435B2 (pt) |
EP (1) | EP3270926B1 (pt) |
JP (1) | JP2018508542A (pt) |
KR (1) | KR20170123697A (pt) |
CN (1) | CN107530343A (pt) |
AU (1) | AU2016233618A1 (pt) |
BR (1) | BR112017019685A2 (pt) |
CA (1) | CA2979222A1 (pt) |
MX (1) | MX2017011935A (pt) |
RU (1) | RU2017134107A (pt) |
WO (2) | WO2016145614A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10195201B2 (en) | 2015-05-05 | 2019-02-05 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors |
BR112018008431A2 (pt) | 2015-11-02 | 2018-11-06 | Janssen Pharmaceutica Nv | composto de [1,2,4]triazolo[1,5-a]pirimidin-7-il |
EA039102B1 (ru) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
EP3535268B1 (en) | 2016-11-02 | 2022-02-09 | Janssen Pharmaceutica NV | [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors |
MY193511A (en) | 2016-11-02 | 2022-10-17 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
CN112996492A (zh) * | 2018-09-05 | 2021-06-18 | 阿姆斯特丹大学 | Pde11或pde2抑制剂用于治疗帕金森氏疾病的用途 |
CN109678848B (zh) * | 2018-12-29 | 2020-10-09 | 浙江工业大学 | 香豆素/吡啶酮杂合衍生物及其制备方法与应用 |
CN114890897A (zh) * | 2022-05-31 | 2022-08-12 | 常州大学 | 一种pde2抑制剂内酯类衍生物及其制备方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID22834A (id) * | 1997-04-25 | 1999-12-09 | Pfizer | Pirazolopimidinona untuk kelainan seksual |
AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
IL139456A0 (en) | 1999-11-08 | 2001-11-25 | Pfizer | Compounds for the treatment of female sexual dysfunction |
DE10064105A1 (de) | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
ES2272712T3 (es) | 2001-05-23 | 2007-05-01 | Merck Frosst Canada Ltd. | Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2. |
CA2463975A1 (en) | 2001-10-26 | 2003-05-01 | Maria Emilia Di Francesco | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
CA2463976C (en) | 2001-10-26 | 2007-02-13 | Benedetta Crescenzi | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
DE10328479A1 (de) * | 2003-06-25 | 2005-01-13 | Bayer Ag | 6-Arylamino-5-cyano-4-pyrimidinone |
WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
AP2006003632A0 (en) | 2003-12-16 | 2006-06-30 | Pfizer Prod Inc | Pyridol[2,3-D] pyrimidine-2,4-Diamines as PDE 2 inhibitors |
EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
US7851472B2 (en) | 2004-09-02 | 2010-12-14 | Nycomed Gmbh | Triazolophthalazines |
ES2397080T3 (es) * | 2005-01-05 | 2013-03-04 | Nycomed Gmbh | Triazoloftalazinas como agentes inhibidores de la PDE2 |
WO2007058646A1 (en) | 2005-11-15 | 2007-05-24 | Bristol-Myers Squibb Company | Hiv integrase inhibitors: cyclic pyrimidinone compounds |
US7897593B2 (en) | 2006-05-30 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
KR20100045497A (ko) | 2007-08-02 | 2010-05-03 | 화이자 인코포레이티드 | 피리미딘 및 피리딘 유도체 및 이들의 약학적 용도 및 조성물 |
US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
AU2009321601B2 (en) * | 2008-12-04 | 2012-11-01 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives |
ME01923B (me) | 2009-05-28 | 2015-05-20 | Novartis Ag | Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina |
US8680116B2 (en) | 2009-07-22 | 2014-03-25 | Merck Sharp & Dohme Corp. | Quinolinone PDE2 inhibitors |
SG192576A1 (en) | 2011-02-23 | 2013-09-30 | Pfizer | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
US9328075B2 (en) * | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
WO2012168817A1 (en) | 2011-06-07 | 2012-12-13 | Pfizer Inc. | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
CA2838645C (en) | 2011-06-27 | 2020-03-10 | Janssen Pharmaceutica Nv | 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives |
US9056863B2 (en) | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
WO2013034758A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Substituted triazolopyrazines and uses thereof |
WO2013034755A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders |
US9200001B2 (en) | 2011-10-06 | 2015-12-01 | Merck Sharp & Dohme Corp. | Triazolyl PDE10 inhibitors |
WO2013074390A1 (en) * | 2011-11-14 | 2013-05-23 | Merck Sharp & Dohme Corp. | Triazolopyridinone pde10 inhibitors |
US8530461B2 (en) | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
NZ631258A (en) | 2012-04-25 | 2016-11-25 | Takeda Pharmaceuticals Co | Nitrogenated heterocyclic compound |
US9527841B2 (en) | 2012-07-13 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors |
US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
WO2014078216A1 (en) * | 2012-11-15 | 2014-05-22 | Merck Sharp & Dohme Corp. | Cyclobutyl benzimidazoles as pde10 inhibitors |
WO2014139983A1 (en) | 2013-03-13 | 2014-09-18 | H. Lundbeck A/S | [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors |
EP3026051A4 (en) | 2013-07-24 | 2017-03-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2015
- 2015-03-17 WO PCT/CN2015/074396 patent/WO2016145614A1/en active Application Filing
-
2016
- 2016-03-11 AU AU2016233618A patent/AU2016233618A1/en not_active Abandoned
- 2016-03-11 KR KR1020177029171A patent/KR20170123697A/ko unknown
- 2016-03-11 WO PCT/US2016/021902 patent/WO2016149058A1/en active Application Filing
- 2016-03-11 JP JP2017548454A patent/JP2018508542A/ja active Pending
- 2016-03-11 US US15/554,614 patent/US10358435B2/en active Active
- 2016-03-11 MX MX2017011935A patent/MX2017011935A/es unknown
- 2016-03-11 BR BR112017019685A patent/BR112017019685A2/pt not_active Application Discontinuation
- 2016-03-11 CA CA2979222A patent/CA2979222A1/en not_active Abandoned
- 2016-03-11 RU RU2017134107A patent/RU2017134107A/ru unknown
- 2016-03-11 EP EP16765473.0A patent/EP3270926B1/en active Active
- 2016-03-11 CN CN201680028025.XA patent/CN107530343A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2017011935A (es) | 2018-02-09 |
JP2018508542A (ja) | 2018-03-29 |
WO2016149058A1 (en) | 2016-09-22 |
WO2016145614A1 (en) | 2016-09-22 |
EP3270926A1 (en) | 2018-01-24 |
US20180237422A1 (en) | 2018-08-23 |
US10358435B2 (en) | 2019-07-23 |
EP3270926A4 (en) | 2018-08-01 |
AU2016233618A1 (en) | 2017-09-14 |
KR20170123697A (ko) | 2017-11-08 |
CA2979222A1 (en) | 2016-09-22 |
CN107530343A (zh) | 2018-01-02 |
EP3270926B1 (en) | 2021-08-04 |
RU2017134107A (ru) | 2019-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017019685A2 (pt) | composto, composição farmacêutica, uso de um composto ou um sal ou um solvato farmaceuticamente aceitável do mesmo, e, método para tratamento de uma doença ou condição | |
BR112014004310B8 (pt) | Composto de pirimidina inibidor da enzima fosfodiesterase 10, composição farmacêutica, uso de um composto | |
BR112017010261A2 (pt) | composto, composição farmacêutica, e, método de tratamento para tratar distúrbios do sistema nervoso central (cns). | |
DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. | |
CL2011002839A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos positivos de receptores mglur2; composición farmacéutica y su proceso de preparacion; combinación farmaceutica; y su uso en el tratamiento o prevencion de un trastorno del sistema nervioso central tal como ansiedad y esquizofrenia, entre otros. | |
CL2011002838A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostéricos de receptores mglur2; composición farmacéutica; proceso para prepararla; y su uso en el tratamiento o la prevención de un trastorno del sistema nervioso central seleccionado de ansiedad y esquizofrenia, entre otros. | |
EA201890650A1 (ru) | ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА | |
MX2017006049A (es) | 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidro piridinas como inhibidores de bace1. | |
MY193511A (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
WO2012044561A3 (en) | 2-alkoxy pyrimidine pde10 inhibitors | |
PH12019501074A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
WO2012044562A3 (en) | Pyrazolopyrimidine pde10 inhibitors | |
IN2015DN00957A (pt) | ||
WO2012054366A3 (en) | Substituted amino-triazolyl pde10 inhibitors | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
PH12018502378A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
MX2019014597A (es) | Inhibidores de pirazolopirimidina de pde9. | |
WO2016051306A3 (en) | Novel anthranilic acid derivatives | |
WO2014150114A8 (en) | Substituted pyridizinone derivatives as pde10 inhibitors | |
BR112023018850A2 (pt) | Pró-drogas de compostos pde10 | |
ECSP14013268A (es) | Inhibidores de pde10 de pirimidina | |
EA201790795A1 (ru) | СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |